Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2023-03-13 00:00:00 ET · period of report 2023-03-13 · accession 0000950170-23-007570 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-13 | 2023-03-13 | VRDN | Myers Scott Dunseth | CEO, Dir | P - Purchase | $29.15 | +5,500 | 255.5K | +2% | +$160.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-13 | P | A | 5,500 | $29.15 | 255,500 | D | — | — |